FINWIRES · TerminalLIVE
FINWIRES

Waratah Minerals Secures AU$48 Million in Institutional Placement; Shares Fall 4%

By

-- Waratah Minerals (ASX:WTM) has secured AU$48 million through a placement to institutional, sophisticated, and professional investors, issuing around 77.4 million new fully paid ordinary shares at AU$0.62 apiece, representing over a 15% discount to its 15-day volume weighted average price, according to a Thursday Australian bourse filing.

The placement is expected to settle on May 13, and the new shares are scheduled to be allotted on May 14, the filing said.

The funds will be used to support extensional and resource drilling at the Spur and Consols gold zones, exploration drilling at the Gazzards, Alpine, and Ironclad zones, metallurgical test work, additional geochemical and geophysical target definition, as well as for working capital, the filing added.

The company's shares fell around 4% in recent Thursday trade.

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661